Rituximab-PECC induction followed by 90Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

Fingerprint

Dive into the research topics of 'Rituximab-PECC induction followed by 90Y-ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT: results from a phase II HOVON study'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science